ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.
Article content
Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies.
Article content
Article content
'We are pleased to welcome Jon to IPA's Board of Directors during this transformative period for the Company,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'Jon brings the rare and highly valuable combination of Nasdaq board governance and senior executive experience—critical as we navigate commercialization and strategic growth. His deep understanding of capital markets and proven success guiding innovation-driven companies aligns well with our strategy to expand adoption of our LENSai™ and HYFT® platforms, and to position IPA at the forefront of AI-powered drug discovery.'
Article content
Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital-raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen.
Article content
Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee, further underscoring his depth of experience in Nasdaq board governance.
Article content
'I'm excited to join IPA's Board at such a pivotal time,' said Mr. Lieber. 'The Company's ability to integrate in silico discovery with translational biology sets it apart in a rapidly evolving biotherapeutics landscape. I look forward to supporting IPA's continued momentum and strategic execution.'
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated contributions of Mr. Lieber to the Company's board and strategic direction, the Company's growth trajectory, and its ability to execute on scientific, commercial, and capital markets initiatives.
Article content
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in leadership dynamics, evolving business strategies, market conditions, regulatory developments, scientific and technological advancements, and other risks related to the Company's operations and industry.
Article content
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should any of these risks materialize actual results could vary significantly from those currently anticipated.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations Contact
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog,
Globe and Mail
22 minutes ago
- Globe and Mail
Celsius Holdings to Participate in Upcoming Investor Conferences
Celsius Holdings, Inc. (Nasdaq: CELH) today announced that the company will participate in the following investor conferences: Barclays 18th Annual Global Consumer Staples Conference Date: Sept. 2-3, 2025 Fireside chat: Sept. 2, approximately 12:00 p.m. EDT Piper Sandler Growth Frontiers Conference Date: Sept. 10, 2025 Fireside chat: Sept. 10, approximately 10:30 a.m. CDT Wells Fargo 8th Annual Consumer Conference Date: Sept. 16-17, 2025 All investors are invited to join live webcasts of the fireside chats at As disclosed in our Annual Report on Form 10-K filed with the Securities & Exchange Commission (the 'SEC') on March 3, 2025, we use our website and webcasts as means of disclosing material information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Attendees are reminded to join the webcast before the planned start time to ensure a good connection and to allow for time to complete the free registration. We intend to make replays of the webcast noted above available on our website for at least 90 days after the original conference date. About Celsius Holdings, Inc. Celsius Holdings, Inc. (Nasdaq: CELH) is a functional beverage company and the owner of energy drink brand CELSIUS ®, hydration brand CELSIUS HYDRATION TM and health and wellness brand Alani Nu ®. Born in fitness and pioneering the rapidly growing, better-for-you, functional beverage category, the company creates and markets leading functional beverage products. For more information, please visit
Globe and Mail
22 minutes ago
- Globe and Mail
Materion to Participate in the Seaport Research Partners Annual Summer Conference
Materion Corporation (NYSE: MTRN) will participate in the Seaport Research Partners Annual Summer Conference on August 20, 2025. Jugal Vijayvargiya, President and Chief Executive Officer and Shelly Chadwick, Vice President, Finance and Chief Financial Officer, will be available for one-on-one meetings with investors throughout the day. About Materion Materion Corporation is a global leader in advanced materials solutions for high-performance industries including semiconductor, industrial, aerospace & defense, energy and automotive. With nearly 100 years of expertise in specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings, Materion partners with customers to enable breakthrough solutions that move the world forward. Headquartered in Mayfield Heights, Ohio, the company employs more than 3,000 people worldwide, serving customers in more than 60 countries.
